A carregar...
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
BACKGROUND: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects. METHODS: Here we describe the cel...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4137066/ https://ncbi.nlm.nih.gov/pubmed/25104095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-570 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
A carregar...